printemailclick to share buttonfacebooktwitterlinkedin
Committee to Evaluate Drugs/CCO Subcommittee (CED-CCO) Reports

(formerly DQTC-SOS Reports)

The Committee to Evaluate Drugs/CCO Subcommittee (CED-CCO) reports are systematically developed statements aimed to assist deliberations of the CED, the committee responsible for making recommendations regarding drug funding. In contrast to clinical practice and organizational guidelines developed by the PEBC, the CED-CCO reports  have not completed the full guideline development cycle.

The PEBC developed the following evidence-based reports in response to requests from the CCO-CED and the DQTC-SOS (Drug Quality Therapeutic Committee’s Standing Oncology Subcommittee, predecessor to CED-CCO). 

CED-CCO reports are not maintained. They remain current for 3 years from the date of publication, then they are archived. The current status of each guidance document is noted beside the title and link as outlined below:

  • Documents listed as CURRENT are 3 years old or less, up-to-date, and can be used for decision making.
  • Documents that are listed as “FOR EDUCATION AND INFORMATION PURPOSES” are documents for which no further updates are planned and whose recommendations may no longer be consistent with recent evidence.  They may be of educational, historical, clinical, or system interest.

The PEBC developed the following evidence-based reports in response to requests from the CCO-CED and the DQTC-SOS.

For Education and Information Purposes 

  • Pemetrexed Monotherapy for the Maintenance Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Non-Squamous Histology
  • Zoledronic Acid Adjuvant Therapy in Combination with Adjuvant Endocrine Therapy for Premenopausal Women with Early-Stage Hormone Receptor Positive Breast Cancer
  • Recombinant Humanized Thyroid Stimulating Hormone (rhTSH) Preparation Prior To Radioiodine Ablation in Patients Who Have Undergone Thyroidectomy for Papillary or Follicular Thyroid Cancer
  • The Use of Imatinib Mesylate (Gleevec TM ) in Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Program in Evidence-Based Care (PEBC)
McMaster University, Juravinski Site
G Wing, 2nd Floor
711 Concession Street
Hamilton, Ontario, Canada
L8V 1C3

Phone: 905.527.4322 ext. 42822
Fax: 905.526.6775
Last modified: Wed, Nov 26, 2014
cancer care ontario | action cancer ontario   620 University Avenue Toronto Ontario, Canada M5G 2L7   Phone: 416.971.9800 Fax: 416.971.6888

Please help improve the quality of our website by answering 10 brief questions in our online survey. Would you like to participate?